共 50 条
Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients
被引:15
|作者:
Xu, L.
[1
]
Anderson, J.
[2
]
Ferns, B.
[3
]
Cook, P.
[1
]
Wildfire, A.
[4
]
Workman, J.
[1
]
Graham, S.
[1
]
Smit, E.
[1
]
机构:
[1] Birmingham Heartlands & Solihull NHS Trust, W Midlands Publ Hlth Lab, Hlth Protect Agcy, Birmingham B9 5SS, W Midlands, England
[2] Homerton Univ Hosp NHS Fdn Trust, London, England
[3] UCL, London, England
[4] Chelsea Westminster Hosp, London, England
关键词:
D O I:
10.1089/aid.2007.0303
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.
引用
收藏
页码:1003 / 1007
页数:5
相关论文